CAR T cells can activate a tolerogenic response similar to endogenous tumor-infiltrating lymphocytes; CAR T cells undergo activation-induced upregulation of regulatory immune checkpoints such as PD-1 and CTLA-4, which can dampen antitumor response (8). Here, PDCD1 is linked to neoplasm.